Roche Launches Comprehensive Liver Disease Panel to Transform Chronic Liver Disease Management
核心洞察
Roche has launched the Liver Disease Panel, the first comprehensive suite of certified algorithms designed to support chronic liver disease management across the patient care pathway.
The panel includes LiverPRO, a CE-marked algorithm requiring only age and three routine blood biomarkers to assess liver fibrosis risk, enabling earlier detection and intervention.
With chronic liver disease affecting 1.5 billion people worldwide and often remaining undiagnosed until advanced stages, the non-invasive panel addresses a critical unmet medical need.
Roche announced the launch of its comprehensive Liver Disease Panel, marking a significant advancement in chronic liver disease (CLD) management through the integration of biomarker-based diagnostics and advanced digital algorithms. The suite represents the company's first digital portfolio specifically designed to support care across key stages of the chronic liver disease pathway, from early risk identification to liver cancer surveillance.
Addressing a Global Health Challenge
Chronic liver disease affects 1.5 billion people worldwide, representing a growing global health challenge that remains widely undiagnosed. The condition often presents without symptoms in early stages, leading to missed opportunities for early intervention and avoidable progression to advanced disease, including cirrhosis and liver cancer. The increasing prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) now affects 38% of the global population and is becoming the fastest-growing cause of liver cancer worldwide.
"Chronic liver disease impacts millions of lives around the world, and patients need effective care at every stage of their journey," said Matt Sause, CEO Roche Diagnostics. "With the Liver Disease Panel, we are enabling clinicians to identify risk earlier, intervene sooner, and manage this disease more effectively, helping to improve liver care and support better patient health."
Revolutionary Algorithm Technology
The Liver Disease Panel includes LiverPRO, a CE-marked algorithm developed through collaboration with health tech company Evido (搜索). This innovative tool adapts to existing patient data, requiring only age and a minimum of three out of nine common blood-based biomarkers to assess the risk of liver fibrosis. By leveraging accessible routine lab results, LiverPRO supports timely intervention, helping clinicians act sooner and improving disease management before patients reach advanced stages of the disease.
LiverPRO has been endorsed in the EASL Patient Trajectory Guidance as an alternative and scalable first-line test for liver fibrosis, confirming that the tool standardizes patient referrals and speeds up the identification of high-risk cases using non-invasive technology.
Comprehensive Digital Portfolio
The Liver Disease Panel brings together clinically validated algorithms into a single, secure platform available on the navify Algorithm Suite. The comprehensive library includes:
- LiverPRO for likelihood of having liver fibrosis
- ADAPT with Roche's Elecsys PRO-C3 for assessing severity of liver fibrosis
- GAAD with Roche's Elecsys AFP and Elecsys PIVKA II for aid in diagnosis of hepatocellular carcinoma (HCC)
- Trusted clinical tools such as the FIB-4 Index, MELD Scores, ALBI Score, Child-Pugh Score, and the Lille Model
Each solution is certified and automated within clinical workflows, ensuring patient data is handled with the highest standards required for a medical device.
Transforming Patient Care Pathways
By combining complementary biomarkers within advanced digital algorithms, the panel helps clinicians make more confident, evidence-based decisions using routinely available clinical data. The solution transforms the patient journey by enabling broader reach and timely patient detection through a scalable approach to assessing fibrosis severity.
Through the integration of biomarker innovation with algorithm analysis, the Liver Disease Panel reduces reliance on invasive tests and provides a proactive, preventive model of care. The panel seamlessly integrates with existing hospital systems, giving clinicians a single point of access to order and view algorithm results.
Market Availability and Platform Integration
The Liver Disease Panel will be available in markets across Europe through the navify platform, which includes more than 130 digital solutions for labs, hospitals and patients worldwide. The navify platform is designed to deliver security at every step of the data analytical process with ISO/IEC 27001 certification for the Information Security Management System, with all data encrypted at rest and in transit.